Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Free Subscription

Articles published in AIDS

Retrieve available abstracts of 48 articles:
HTML format

Single Articles

    February 2024
  1. DAUBY N, Gagneux-Brunon A, Martin C, Mussi-Pinhata MM, et al
    Maternal immunization in women living with HIV.
    AIDS. 2024;38:137-144.
    PubMed     Abstract available

    January 2024
  2. DUNCAN MC, Omondi FH, Kinloch NN, Lapointe HR, et al
    Effects of COVID-19 mRNA vaccination on HIV viremia and reservoir size.
    AIDS. 2024 Jan 15. doi: 10.1097/QAD.0000000000003841.
    PubMed     Abstract available

  3. BLAZKOVA J, Shi V, Manning MR, Kennedy BD, et al
    Effect of influenza vaccination on the persistence of HIV reservoirs and immunologic parameters in people with HIV.
    AIDS. 2024;38:131-133.

  4. VOLKOW P, Islas-Munoz B, Carpio-Guadarrama D, Perez-Padilla R, et al
    Exacerbation of Kaposi sarcoma after MVA-BN (Jynneos) vaccination in a person with HIV/AIDS.
    AIDS. 2024;38:129-130.

    December 2023
  5. JACOBSON JM, Felber BK, Chen H, Pavlakis GN, et al
    The immunogenicity of an HIV-1 gag conserved element DNA vaccine in people with HIV and receiving antiretroviral therapy.
    AIDS. 2023 Dec 4. doi: 10.1097/QAD.0000000000003804.
    PubMed     Abstract available

    November 2023
  6. KAUR G, Perry RT
    Preventing measles in children and adolescents with HIV.
    AIDS. 2023;37:2087-2089.

    October 2023
  7. CHAMMARTIN F, Griessbach A, Kusejko K, Audige A, et al
    Bridging the Gap: identifying factors impacting mRNA SARS-CoV-2 vaccine booster response in people living with HIV-1.
    AIDS. 2023 Oct 12. doi: 10.1097/QAD.0000000000003751.
    PubMed     Abstract available

    September 2023
  8. NUNES MC, Tamblyn A, Jose L, Ntsimane M, et al
    Immunogenicity of tetanus, diphtheria and acellular pertussis vaccination among pregnant women living with and without HIV.
    AIDS. 2023 Sep 29. doi: 10.1097/QAD.0000000000003731.
    PubMed     Abstract available

  9. RACCAGNI AR, Diotallevi S, Lolatto R, Lucente MF, et al
    Viral blips and virologic failures following mpox vaccination with MVA-BN among people with HIV.
    AIDS. 2023 Sep 29. doi: 10.1097/QAD.0000000000003733.
    PubMed     Abstract available

    August 2023
  10. MOTTA E, Camacho LAB, Cunha M, de Filippis AB, et al
    Immunogenicity and reactogenicity of yellow fever vaccine in people living with HIV.
    AIDS. 2023 Aug 24. doi: 10.1097/QAD.0000000000003696.
    PubMed     Abstract available

  11. COSTINIUK CT, Singer J, Lee T, Galipeau Y, et al
    Antibody neutralization capacity after COVID-19 vaccination in people with HIV (CIHR Canadian HIV trials network 328).
    AIDS. 2023 Aug 3. doi: 10.1097/QAD.0000000000003680.
    PubMed     Abstract available

  12. AHMAD A, Samarani S, Costiniuk CT
    Antibody and T-cell responses elicited by coronavirus disease 2019 vaccination in people with HIV-1: the case of late presenters.
    AIDS. 2023;37:1625-1627.

    June 2023
  13. MUTEMBO S, Yang Y, Carcelen A, Winter AK, et al
    Measles immunity gaps among children and adolescents with HIV in zambia despite high measles vaccination and antiretroviral therapy coverage.
    AIDS. 2023 Jun 29. doi: 10.1097/QAD.0000000000003634.
    PubMed     Abstract available

  14. SHUBIN Z, Stanfield-Oakley S, Puangkaew J, Pitisutthithum P, et al
    Additional boosting to the RV144 vaccine regimen increased Fc-mediated effector functions magnitude but not durability.
    AIDS. 2023 Jun 1. doi: 10.1097/QAD.0000000000003611.
    PubMed     Abstract available

    May 2023
  15. AUGELLO M, Bono V, Rovito R, Tincati C, et al
    Six-month immune responses to mRNA-1273 Vaccine in cART-treated late presenter people living with HIV according to previous SARS-CoV-2 Infection.
    AIDS. 2023 May 5. doi: 10.1097/QAD.0000000000003585.
    PubMed     Abstract available

    April 2023
  16. GRIFFIN DW, Pai Mangalore R, Hoy JF, Mcmahon JH, et al
    Immunogenicity, effectiveness and safety of SARS-CoV-2 vaccination in people living with HIV: A systematic review and meta-analysis.
    AIDS. 2023 Apr 14. doi: 10.1097/QAD.0000000000003579.
    PubMed     Abstract available

  17. VON TOKARSKI F, Fourn E, Faucheron A, Chan Hew Wai A, et al
    Smallpox vaccine acceptability among French men having sex with men living with HIV in settings of monkeypox outbreak.
    AIDS. 2023;37:855-856.

  18. SU B, Vanham G
    Effectiveness of COVID-19 primary and booster vaccination in HIV-infected individuals.
    AIDS. 2023;37:837-839.

    March 2023
  19. WILCK M, Barnabas S, Chokephaibulkit K, Violari A, et al
    A phase 3 study of safety and immunogenicity of V114, a 15-valent PCV, followed by PPSV23, in children living with HIV.
    AIDS. 2023 Mar 20. doi: 10.1097/QAD.0000000000003551.
    PubMed     Abstract available

  20. COVID-19 vaccine immunogenicity in people with HIV: Erratum.
    AIDS. 2023;37:559.

    February 2023
  21. CHEUNG PK, Lapointe HR, Sang Y, Ennis S, et al
    SARS-CoV-2 live virus neutralization after four COVID-19 vaccine doses in people with HIV receiving suppressive ART.
    AIDS. 2023 Feb 14. doi: 10.1097/QAD.0000000000003519.
    PubMed     Abstract available

  22. CASADO JL, Vizcarra P, Martin-Colmenarejo S, Del Pino J, et al
    Lower T cell response against SARS-CoV-2 variants of concern after mRNA vaccine and risk of breakthrough infections in people living with HIV.
    AIDS. 2023 Feb 8. doi: 10.1097/QAD.0000000000003504.
    PubMed     Abstract available

  23. SOOKAROMDEE P, Wiwanitkit V
    Coronavirus disease 2019 vaccine effectiveness among a population-based cohort of people with HIV.
    AIDS. 2023;37:365-366.

  24. MARTIN C, Domingo C, Hainaut M, Delforge M, et al
    Seroconversion and persistence of neutralizing antibody response after yellow fever vaccination in patients with perinatally acquired HIV infection.
    AIDS. 2023;37:341-346.
    PubMed     Abstract available

    January 2023
  25. MAUAS R, Urena A, Cecchini D, Strada ML, et al
    Adverse events and SARS-CoV-2 antibody responses after immunization with sputnik V, ChAdOx1-S and BBIBP-CorV vaccines in people with HIV.
    AIDS. 2023 Jan 16. doi: 10.1097/QAD.0000000000003483.
    PubMed     Abstract available

  26. MCMAHON WC, Kwatra G, Izu A, Koen AL, et al
    T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa.
    AIDS. 2023;37:105-112.
    PubMed     Abstract available

  27. COSTINIUK CT, Singer J, Lee T, Langlois MA, et al
    COVID-19 vaccine immunogenicity in people with HIV.
    AIDS. 2023;37:F1-F10.
    PubMed     Abstract available

    December 2022
  28. LAPOINTE HR, Mwimanzi F, Cheung PK, Sang Y, et al
    Antibody response durability following three-dose COVID-19 vaccination in people with HIV receiving suppressive ART.
    AIDS. 2022 Dec 23. doi: 10.1097/QAD.0000000000003469.
    PubMed     Abstract available

    October 2022
  29. CHAMBERS C, Samji H, Cooper CL, Costiniuk CT, et al
    COVID-19 Vaccine Effectiveness among a Population-based Cohort of People Living with HIV.
    AIDS. 2022 Oct 19. pii: 00002030-990000000-00126.
    PubMed     Abstract available

  30. WONG NS, Wong BCK, Chan JMC, Wong KH, et al
    Humoral responses to coronavirus disease 2019 vaccines in people with HIV: authors' reply.
    AIDS. 2022;36:1747-1748.

    Surrogate neutralization responses following SARS-CoV-2 vaccination in people with HIV.
    AIDS. 2022;36:1746-1747.

    August 2022
  32. THINDWA D, Mwalukomo TS, Msefula J, Jambo KC, et al
    Risk factors for pneumococcal carriage in adults living with HIV on antiretroviral therapy in the infant pneumococcal vaccine era in Malawi.
    AIDS. 2022 Aug 22. pii: 00002030-990000000-00094.
    PubMed     Abstract available

  33. CHAMMARTIN F, Kusejko K, Pasin C, Trkola A, et al
    Determinants of antibody response to severe acute respiratory syndrome coronavirus 2 mRNA vaccines in people with HIV.
    AIDS. 2022;36:1465-1468.
    PubMed     Abstract available

    July 2022
  34. GIANSERRA L, Dona MG, Giuliani E, Stingone C, et al
    High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV - but HIV viremia matters?
    AIDS. 2022;36:1319-1320.

  35. WOLDEMESKEL BA, Karaba AH, Garliss CC, Beck EJ, et al
    Decay of coronavirus disease 2019 mRNA vaccine-induced immunity in people with HIV.
    AIDS. 2022;36:1315-1317.
    PubMed     Abstract available

  36. CRUM NF, Ahmad A
    Immunity against measles in people with HIV: the need for more research and surveillance.
    AIDS. 2022;36:1305-1306.

    June 2022
  37. POURCHER V, Belin L, Soulie C, Rosenzwajg M, et al
    High seroconversion rate and SARS-CoV-2 Delta neutralization in PLWHIV vaccinated with BNT162b2.
    AIDS. 2022 Jun 23. pii: 00002030-990000000-00043.
    PubMed     Abstract available

    April 2022
  38. WONG NS, Wong BCK, Chan JMC, Wong KH, et al
    Surrogate neutralisation responses following SARS-CoV-2 vaccination in people living with HIV - comparison between inactivated and mRNA vaccine.
    AIDS. 2022 Apr 23. pii: 00002030-990000000-00010.
    PubMed     Abstract available

    March 2022
  39. LEFEBVRE M, Secher S, Bouchez S, Vandamme YM, et al
    Measles seroprevalence in human immunodeficiency virus-infected adults born in the era of measles vaccination.
    AIDS. 2022 Mar 8. pii: 00002030-990000000-00002.
    PubMed     Abstract available

  40. XU X, Vesterbacka J, Aleman S, Nowak P, et al
    High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV - but HIV viremia matters?
    AIDS. 2022;36:479-481.
    PubMed     Abstract available

    February 2022
  41. DURIER C, Mercier-Delarue S, Verdiere NC, Meiffredy V, et al
    A 5-year neutralizing immune response to yellow fever vaccine in HIV-infected and HIV-uninfected adults.
    AIDS. 2022;36:319-321.

  42. SHAVER ZM, Anderson M, Bhebhe L, Baruti K, et al
    Decreased HBV vaccine response among HIV positive infants compared to HIV negative infants in Botswana.
    AIDS. 2022 Feb 1. pii: 00002030-900000000-96228.
    PubMed     Abstract available

    January 2022
  43. HASSOLD N, Brichler S, Ouedraogo E, Leclerc D, et al
    Impaired antibody response to COVID-19 vaccination in advanced HIV infection.
    AIDS. 2022 Jan 10. pii: 00002030-900000000-96241.
    PubMed     Abstract available

  44. ALEDO MG, Canizares A, Vazquez-Rodriguez P, Castro A, et al
    Safety and immunogenicity of SARS-CoV-2 mRNA-1273 and BNT162b2 vaccines in people living with HIV.
    AIDS. 2022 Jan 6. pii: 00002030-900000000-96246.
    PubMed     Abstract available

    December 2021
  45. SPINELLI MA, Brown LB, Glidden DV, Hunter K, et al
    SARS-CoV-2 incidence, testing rates, and severe COVID-19 outcomes among people with and without HIV.
    AIDS. 2021;35:2545-2547.
    PubMed     Abstract available

    November 2021
  46. MOHAPI L, Pinedo Y, Osiyemi O, Supparatpinyo K, et al
    Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV: a randomized phase 3 study.
    AIDS. 2021 Nov 8. pii: 00002030-900000000-96271.
    PubMed     Abstract available

    August 2021
  47. MARASINI B, Vyas HK, Lakhashe SK, Hariraju D, et al
    Mucosal AIDS virus transmission is enhanced by antiviral IgG isolated early in infection.
    AIDS. 2021 Aug 16. pii: 00002030-900000000-96332.
    PubMed     Abstract available

    June 2021
  48. LIU G, Mugo NR, Brown ER, Mgodi NM, et al
    Prevalent HPV infection increases the risk of HIV acquisition in African women: advancing the argument for HPV immunization.
    AIDS. 2021 Jun 24. pii: 00002030-900000000-96360.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.